1.Bouzeghrane, F, Naggara, O, Kallmes, DF, Berenstein, A, Raymond, J, International Consortium of Neuroendovascular Centres. In vivo experimental intracranial aneurysm models: a systematic review. AJNR Am J Neuroradiol. 2010;31(3):7–23.
2.Fujii, M, Yan, J, Rolland, WB, Soejima, Y, Caner, B, Zhang, JH.Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4(4):7–46.
3.Chalouhi, N, Ali, MS, Starke, RM, et al. Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm. 2012;2012:271582.
4.Sima, X, Xu, J, Li, J, You, C.Association between NFKB1–94 insertion/deletion ATTG polymorphism and risk of intracranial aneurysm. Genet Test Mol Biomarkers. 2013;17(8):7–4.
5.Aoki, T, Kataoka, H, Shimamura, M, et al. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation. 2007;116 (24):2830–40.
6.Zhang, HF, Zhao, MG, Liang, GB, Song, ZQ, Li, ZQ.Expression of pro-inflammatory cytokines and the risk of intracranial aneurysm.Inflammation. 2013. (EPUB AHEAD OF PRINT).
7.Ishikawa, Y, Gohda, T, Tanimoto, M, et al. Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res. 2012;2012:702948.
8.Pannu, H, Kim, DH, Guo, D, et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg. 2006;105(3):7–23.
9.Caird, J, Napoli, C, Taggart, C, Farrell, M, Bouchier-Hayes, D.Matrix metalloproteinases 2 and 9 in human atherosclerotic and non-atherosclerotic cerebral aneurysms. Eur J Neurol. 2006;13(10): 1098–105.
10.Low, SK, Zembutsu, H, Takahashi, A, et al. Impact of LIMK1, MMP2 and TNF-alpha variations for intracranial aneurysm in Japanese population. J Hum Genet. 2011;56(3):7–16.
11.Shin, S, Cho, YP, Jun, H, Park, H, Hong, HN, Kwon, TW.Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix. J Vasc Surg. 2013;57(5):7–70.
12.Allaire, E, Schneider, F, Saucy, F, et al. New insight in aetiopathogenesis of aortic diseases. Eur J Vasc Endovasc Surg. 2009;37(5):7–7.
13.Siefert, SA, Sarkar, R.Matrix metalloproteinases in vascular physiology and disease. Vascular. 2012;20(4):7–16.
14.Kosierkiewicz, TA, Factor, SM, Dickson, DW.Immunocytochemical studies of atherosclerotic lesions of cerebral berry aneurysms. J Neuropathol Exp Neurol. 1994;53(4):7–406.
15.Nakayama, K.cAMP-response element-binding protein (CREB) and NF-kappaB transcription factors are activated during prolonged hypoxia and cooperatively regulate the induction of matrix metalloproteinase MMP1. J Biol Chem. 2013;288(31): 22584–95.
16.Konig, HG, Fenner, BJ, Byrne, JC, et al. Fibroblast growth factor homologous factor 1 interacts with NEMO to regulate NF-kappaB signaling in neurons. J Cell Sci. 2012;125 (Pt 24): 6058–70.
17.Zhou, H, Zhao, K, Li, W, et al. The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR- and NF-kappaB-related signaling pathways. Biomaterials. 2012;33(29):7–42.
18.Vigetti, D, Genasetti, A, Karousou, E, et al. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-kappaB (NF-kappaB) pathway. J Biol Chem. 2010;285(32):7–45.
19.Gomez-Pina, V, Martinez, E, Fernandez-Ruiz, I, et al. Role of MMPs in orchestrating inflammatory response in human monocytes via a TREM-1-PI3K-NF-kappaB pathway. J Leukoc Biol. 2012;91 (6):933–45.
20.Dambach, DM, Durham, SK, Laskin, JD, Laskin, DL.Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. Toxicol Appl Pharmacol. 2006;211(2):7–65.
21.Aoki, T, Kataoka, H, Ishibashi, R, Nozaki, K, Egashira, K, Hashimoto, N.Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke. 2009;40(3):7–51.
22.Aoki, T, Kataoka, H, Morimoto, M, Nozaki, K, Hashimoto, N.Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke. 2007;38 (1):162–9.
23.Huusko, T, Salonurmi, T, Taskinen, P, et al. Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic aneurysms. J Thorac Cardiovasc Surg. 2013;145(4):7–23.
24.Hellenthal, FA, Ten Bosch, JA, Pulinx, B, et al. Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg. 2012;43(2):171–2.